1 Guidance

1 Guidance

1.1 Obinutuzumab, in combination with chlorambucil, is recommended as an option for adults with untreated chronic lymphocytic leukaemia who have comorbidities that make full‑dose fludarabine‑based therapy unsuitable for them, only if:

  • bendamustine‑based therapy is not suitable and

  • the company provides obinutuzumab with the discount agreed in the patient access scheme.

1.2 People whose treatment with obinutuzumab is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.

  • National Institute for Health and Care Excellence (NICE)